AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 92 min read$TYRA

Why Is Tyra Biosciences Stock Sinking Wednesday? - Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA) shares fell 21.6% after Phase 2 trial results for dabogratinib showed an 86% overall response rate in patients with target exposure, but a 57% complete response rate at 60 mg, below analyst expectations of 70-80%. The company plans to advance to Phase 3 development and expand the study to a 70 mg cohort. Initial upper tract urothelial cancer study results were positive.

Original reporting
benzinga.com
Published Sep 9, 2026, 4:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why Is Tyra Biosciences Stock Sinking Wednesday? - Tyra Biosciences (NASDAQ:TYRA) — source image
Source · benzinga.com
Decision brief

The 30-second read

$TYRABearishHigh
01

Why it matters

The Phase 2 readout provides the first efficacy data for dabogratinib, directly influencing market perception and share price.

02

Market read

New clinical data caused a sharp intra‑day decline, highlighting immediate trading relevance for TYRA and peers.

03

What to watch

The trial identified a clear exposure‑response relationship and plans for a 70 mg cohort, which could improve future outcomes.

Relevance 8/10Novelty 8/10Timing: Wednesday pre‑market

Background

Tyra Biosciences is a Nasdaq‑listed biotech focused on FGFR3‑altered bladder cancer therapies.

Company-level read

Ticker impact

$TYRABearishHigh confidence
Context

Tyra Biosciences disclosed Phase 2 SURF302 trial results showing lower-than-expected complete response rates, triggering a 21.6% share drop.

Expected impact

Further downside pressure if Phase 3 outlook remains uncertain.

Evidence & confidence

The trial's 57% CR rate versus expected 70‑80% is a material new fact that moved the stock sharply on the day of release.

Market effects

Sector

Biotech sector may see heightened scrutiny of early‑stage oncology trials.

Regional

U.S. biotech investors could reassess risk on similar FGFR3‑targeted programs.

Global

Limited to companies with comparable bladder cancer pipelines.

Counterpoint

What could challenge this read

Some investors may view the 86% overall response as a positive signal despite lower CR, supporting a longer‑term hold.

Key entities

  • Company
    Tyra Biosciences Inc.

    Developer of dabogratinib for bladder cancer.

  • Analyst
    William Blair

    Commented on the stock plunge due to trial results.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 9
$TYRAHighAI 8/10

Why is Tyra Biosciences stock plunging today?

Tyra Biosciences (TYRA) stock fell 31.1% to $18.42 after Phase 2 trial results for dabogratinib showed a 64% complete response rate, below the 70% analyst consensus. Piper Sandler and H.C. Wainwright had modeled a 70% rate as the success threshold. The stock had risen 13% the prior week. Broader market caution added to the decline.

investing.com2 min
SEP 9
$TYRAHighAI 9/10

Tyra Biosciences stock tumbles 30% on phase 2 trial results

Tyra Biosciences (NASDAQ: TYRA) shares dropped 30% after reporting Phase 2 trial results for dabogratinib. The drug showed a 79% overall response rate and 64% complete response rate in combined patients. The trial enrolled 44 participants, with safety results indicating low rates of severe adverse events. Tyra plans to continue enrollment and engage with health authorities for Phase 3 study design.

investing.com2 min
SEP 8
$TYRAMed

Piper Sandler reiterates Tyra Biosciences stock rating ahead of data

Piper Sandler reiterated an Overweight rating and $56 price target for Tyra Biosciences (NASDAQ: TYRA) ahead of clinical trial data. The stock has risen 13% in a week and 136% in a year, trading at $28.60. Piper Sandler expects a 70% response rate for dabogratinib in bladder cancer trials, which could advance the drug to Phase 3. The firm sees a $1B+ opportunity in this market. Other analysts also maintain Buy ratings with targets up to $45.

investing.com2 min